Current Oncology · 2021 · 16 citations · 25 references
MedicineNeurosurgeryOncologyDiagnostic ImagingNeuro-oncologyNeuroradiologyBrain TumorsCancer Survival AnalysisGlioblastomaMalignant TumorsNeuro-oncologic ImagingNeuro-oncology ImagingGlioblastoma ImagingGlioblastoma PrognosisResidual Tumor EvaluationTumor Necrosis AssessmentTumor Necrosis PatternsTumor Volume MeasurementUnivariate Analysis
Primary glioblastoma (GBM), IDH-wildtype, especially with multifocal appearance/growth (mGBM), is associated with very poor prognosis. Several clinical parameters have been identified to provide prognostic value in both unifocal GBM (uGBM) and mGBM, but information about the influence of radiological parameters on survival for mGBM cohorts is scarce. This study evaluated the prognostic value of several volumetric parameters derived from magnetic resonance imaging (MRI). Data from the Department of Neurosurgery, Leipzig University Hospital, were retrospectively analyzed. Patients treated between 2014 and 2019, aged older than 18 years and with adequate peri-operative MRI were included. Volumetric assessment was performed manually. One hundred and eighty-three patients were included. Survival of patients with mGBM was significantly shorter (p < 0.0001). Univariate analysis revealed extent of resection, adjuvant therapy regimen, residual tumor volume, tumor necrosis volume and ratio of tumor necrosis to initial volume as statistically significant for overall survival. In multivariate Cox regression, however, only EOR (for uGBM and the entire cohort) and adjuvant therapy were independently significant for survival. Decreased ratio of tumor necrosis to initial tumor volume and extent of resection were associated with prolonged survival in mGBM but failed to achieve statistical significance in multivariate analysis.
25
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Michael Weller, Martin J. van den Bent, Kirsten Hopkins et al. · The Lancet Oncology · 2014 · 755 citations · Full text
Medicine, Neurosurgery, Oncology +14